You have successfully logged out.
Not registered yet?
SeQuent® DCBs
Backing up cardiologists with unparalleled clinical data and proven performance for both paclitaxel and sirolimus coated balloons.
Paclitaxel and sirolimus coated balloons
Paclitaxel coated balloon
B. Braun´s paclitaxel coated balloon SeQuent® Please NEO is the best investigated DCB [1] in the field of percutaneous coronary interventions (PCI). It has demonstrated its convincing performance, efficacy and safety in more than 110 published studies (including more than 35 RCTs) – with over 25,000 documented patients, conducted in more than 20 countries.
2020 | Primary Investigator: Jeger R | Study Aim: SQP vs. DES, Vessel: RD ≤ 3 mm | (Primary) Endpoint: MACE @ 36-month follow-up | Patients: 758
Summary BASKET-SMALL 22017 | Primary Investigator: Funatsu A | Study Aim: DCB vs. POBA, Vessel: RD ≤ 2.75 mm, ≥ 2 mm | (Primary) Endpoint: TVF @ 6-month follow-up | Patients: 135
Summary PEPCAD Japan SVD2017 | Primary Investigator: Gobić D | Study Aim: DCB vs. DES, Patients: STEMI (< 12 h) | (Primary) Endpoint: MACE, LLL @ 6-month follow-up | Patients: 75
Summary AMI Feasibility Study2016 | Primary Investigator: Nishiyama N | Study Aim: DCB vs. DES | (Primary) Endpoint: TLR @ 8-month follow-up | Patients: 60
Summary Clinical Value "Stent-less" PCI2019 | Primary Investigator: Rosenberg M | Study Aim: DCB – ISR & De Novo | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 1,025
Summary DCB-only All-Comers Registry2016 | Primary Investigator: Shin E | Study Aim: DCB – De Novo, Vessel: RD ≤ 3.5 mm, ≥ 2.5 mm | (Primary) Endpoint: LLL, FFR @ 9-month follow-up, MI, TLR @ 12-month follow-up | Patients: 67
Summary FFR-Guided DCB-Angioplasty2014 | Primary Investigator: Zeymer U | Study Aim: DCB – De Novo, Vessel: RD ≤ 2.75 mm, ≥ 2.0 mm | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 447
Summary SVD Registry2023 | Primary Investigator: Shin ES | Study Aim: Investigate the impact of DCB-based treatment on PCI for multivessel CAD | (Primary) Endpoint: MACE @ 24-months (cardiac death, MI, TVR, stroke, stent thrombosis and major bleeding) | Patients: 508
Summary DCB-based PCI in Multi-Vessel-DiseaseTreatment methodology
Lesion preparation | |
Acceptable angiographic result
| Unacceptable angiographic result
|
[1] All numbers referring to clinical coronary trials on PCBs, patients enrolled therein and countries in which these trials were conducted, are based on a PubMed literature search conducted with due diligence in February/March 2022. (Data on file at B. Braun)
[2] Ali RM et al J Am Coll Cardiol Intv 2019;12:558-66
[3] Scheller B et al. Circ Cardiovasc Interv. 2022 Sep;15(9):e012305.
[4] Ahmad WAW et al. JACC Cardiovasc Interv. 2022 Apr 11;15(7):770-779
[5] Clever et al. Circ Cardiovasc Interv. 2016 Apr;9(4):e003543.
[6] Kleber FX et al. Clin Res Cardiol. 2013 Nov;102(11):785-97.
[7] Jeger RV et JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402.
With your personalized account, your online experience will be easier, more comfortable and safe.